A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : anti-PD-1 / anti-programmed cell death-1

[Related PubMed/MEDLINE]
Total Number of Papers: 44
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   anti-PD-1  (>> Co-occurring Abbreviation)
Long Form:   anti-programmed cell death-1
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Acquired lipodystrophy associated with immune checkpoint inhibitors. AGL
2020 Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients. AM, LDH, OS
2020 Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. HCC, ICI
2020 Efficacy of Cytotoxic Agents After Progression on Anti-PD-(L)1 Antibody for Pre-treated Metastatic Gastric Cancer. AEs, CTx, MGC
2020 Immune Checkpoint Inhibitors for Patients Aged ≥ 75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-Analysis. anti-CTLA-4, anti-PD-L1, CIs, HRs, ICIs
2020 Mimetic Heat Shock Protein Mediated Immune Process to Enhance Cancer Immunotherapy. DCs, HSPs, nChap
2020 PD-1 blockade inhibits osteoclast formation and murine bone cancer pain. ---
2020 Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients. NK, NSCLC, NSFC, OS, PD-L1, PFS, TPS
2020 Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. NSCLC, PFS, sCD40L, sCD44, sPD-1, sPD-L1, VEGF-A
10  2020 Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration. AE, DRESS, IL
11  2020 Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. ESMO, NGS, NSCLC, TMB
12  2019 A Case Report of Graves' Disease Induced by the Anti-Human Programmed Cell Death-1 Monoclonal Antibody Pembrolizumab in a Bladder Cancer Patient. GD, TRAb
13  2019 A review of avelumab in locally advanced and metastatic bladder cancer. anti-PD-L1, BCG, FDA
14  2019 Acquired Generalized Lipodystrophy: A New Cause of Anti-PD-1 Immune-Related Diabetes. AGL
15  2019 Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma. IDH, oHSVs, ULBP3
16  2019 Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel. anti-PD-L1, CGP, TMB, tTMB, WES
17  2019 Atezolizumab-Induced Autoimmune Diabetes in a Patient With Metastatic Lung Cancer. anti-PD-L1, DKA, HLA, ICIs
18  2019 Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients. IQR
19  2019 Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma. HCC, PD-L1
20  2019 Efficacy of irinotecan-based chemotherapy after exposure to an anti-PD-1 antibody in patients with advanced esophageal squamous cell carcinoma. 5-FU, DCR, ESCC, ORR, OS, PFS
21  2019 Esophageal Stricture Following Radiation, Concurrent Immunochemotherapy, Treated With Hyperbaric Oxygen and Dilation. ---
22  2019 Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy. ---
23  2019 Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review. anti-CTLA-4, ICI
24  2019 Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma. ---
25  2018 Anti-programmed cell death-1 therapy-associated bullous disorders: a systematic review of the literature. BP, EM, SJS, TEN
26  2018 Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy. HCC
27  2018 Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma. BCC, BRAFi, cuSCC
28  2018 Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors. ---
29  2018 Role of immunotherapy in bladder cancer: past, present and future. anti-PDL-1
30  2018 Sick sinus syndrome associated with anti-programmed cell death-1. ---
31  2018 Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases. MBM, OS, PB, SRS
32  2017 Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients. ctDNA
33  2017 Glycogen Synthase Kinase 3 Inactivation Compensates for the Lack of CD28 in the Priming of CD8+ Cytotoxic T-Cells: Implications for anti-PD-1 Immunotherapy. CTLs, GSK, siRNAs, SMIs
34  2017 Hair Repigmentation During Immunotherapy Treatment With an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer. AE, anti-PD-L1, HR, LC, NSCLC
35  2017 Histologic Assessment of Lichenoid Dermatitis Observed in Patients With Advanced Malignancies on Antiprogramed Cell Death-1 (anti-PD-1) Therapy With or Without Ipilimumab. ---
36  2017 Intracorneal pustular drug eruption, a novel cutaneous adverse event in anti-programmed cell death-1 patients that highlights the effect of anti-programmed cell death-1 in neutrophils. ---
37  2017 Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody. EGFR, EGFR-TKI, ILD
38  2017 Severe cytokine release syndrome in a patient receiving PD-1-directed therapy. CRS
39  2016 Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies. BP
40  2016 Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting. DC, NSCLC, TC
41  2016 Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies. mAbs, PD-L1
42  2016 The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1. EBV, GCs, MMR, MSI, PD-L1, TIL
43  2014 Multicenter validation study of anti-programmed cell death-1 antibody as a serological marker for type 1 autoimmune hepatitis. AIH, DILI
44  2013 What lies within: novel strategies in immunotherapy for non-small cell lung cancer. NSCLC